Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H12N2O2S
CAS Number:
Molecular Weight:
248.30
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41106305
MDL number:
InChI key
ZJKNESGOIKRXQY-UHFFFAOYSA-N
SMILES string
CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2
InChI
1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
form
solid
color
light yellow
solubility
DMSO: soluble 28 mg/mL
Quality Level
Gene Information
human ... PDE3A(5139), PDE3B(5140)
Related Categories
Biochem/physiol Actions
Selective phosphodiesterase III (PDE3) inhibitor. Prevents the degradation of cAMP by PDE. Increased cAMP results in enhanced contractility of the heart.
Selective phosphodiesterase III (PDE3) inhibitor. Prevents the degradation of cAMP by PDE.
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R C Dage et al.
Cardiology, 77 Suppl 3, 2-13 (1990-01-01)
Enoximone is an inotropic vasodilating agent. Its principal effects are positive inotropism and vasodilation, which are not accompanied by changes in myocardial oxygen consumption. An inotropic dose of enoximone increases the level of cyclic AMP in the isolated, blood-perfused dog
H J Gilfrich et al.
Zeitschrift fur Kardiologie, 80 Suppl 4, 93-97 (1991-01-01)
Enoximone, a new phosphodiesterase-inhibitor with positive inotropic and vasodilating activities is available for intravenous use in patients with severe heart failure. A review of the current knowledge regarding the adverse effects of this substance reveals that they are characterized by
Marco Metra et al.
European heart journal, 30(24), 3015-3026 (2009-08-25)
Use of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase benefit-risk ratio. We investigated the effects of
E Jähnchen et al.
Zeitschrift fur Kardiologie, 80 Suppl 4, 21-26 (1991-01-01)
Enoximone belongs to the imidazole class of compounds, that possess positive inotropic and vasodilatory activities. These pharmacologic effects are caused by selective inhibition of a cAMP-specific phosphodiesterase in the heart and in the smooth muscle of blood vessels. Results obtained
D Trenk et al.
Zeitschrift fur Kardiologie, 83 Suppl 2, 7-14 (1994-01-01)
Enoximone is an imidazole derivative which proved to be a selective inhibitor of the isoenzymes III/IV of the cAMP-specific phosphodiesterase. It has been shown in various experimental models that the drug exerts both positive inotropic and vasodilating properties which can
Articles
Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service